



## VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit

July 12, 2022

*Leaders will explore public and private sector solutions to social challenges*

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 12, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that its [Chief Executive Officer, Shawn K. Singh](#), will join [U.S. Surgeon General, Vice Admiral Vivek H. Murthy, MD, MBA](#), at the 2022 Concordia Americas Summit to discuss America's ongoing mental health crisis. To attend the 2022 Americas Summit, you can sign up for an in-person pass or a complimentary digital pass [here](#).

Mr. Singh and Dr. Murthy will discuss rising rates of anxiety and depression disorders and the ways in which the COVID-19 pandemic has impacted the mental health landscape in the U.S., including improving access to treatment and diminishing stigma around seeking care and resources. In this timely fireside chat, they will highlight how the public and private sectors can work together to advance critical mental health care initiatives.

"I am honored to join U.S. Surgeon General Murthy at this important moment in history when so many communities are seeking solutions to escalating mental health challenges," said Mr. Singh. "VistaGen is helping lead the way by developing innovative therapies designed to change the trajectory of mental health care — one mind at a time."

### 2022 Concordia Americas Summit

Topic: Addressing the Mental Health Crisis

Date: Thursday, July 14, 2022

Time: 11:40 a.m. to 12:00 p.m. Eastern Time

The discussion between Mr. Singh and Dr. Murthy is open to registered attendees. It will be accessible via live stream on [Concordia's digital platform](#), then posted on [Concordia's YouTube](#) channel. A link will also be available on the 'Events' page of the 'Investors' section on [VistaGen's website](#).

### About VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing drug candidates with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen's clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen's lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with topline results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at [www.VistaGen.com](http://www.VistaGen.com).

### About Concordia Americas Summit

The sixth Concordia Americas Summit is taking place in partnership with the General Secretariat of the Organization of American States at the University of Miami and digitally on July 13-14. Concordia's longest-standing regional initiative, the 2022 Americas Summit will continue its legacy of gathering leaders from across industries, sectors, and geographies to confront the biggest challenges and opportunities facing the Western Hemisphere. To register or find more information about the event, visit the [event webpage](#).

### Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "project," "outlook," "strategy," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "strive," "goal," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by VistaGen and its management, are inherently uncertain. The Company's actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties relating to delays in launching, conducting and/or completing ongoing and planned clinical trials, including delays due to the impact of the ongoing COVID-19 pandemic; fluctuating costs of materials and other resources required to conduct the Company's ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; adverse healthcare reforms and changes of laws and regulations; manufacturing and marketing risks, which may include, but are not limited to, unavailability of or delays in delivery of raw materials for manufacture of the Company's CNS drug candidates due to the ongoing COVID-19 pandemic or otherwise; inadequate and/or untimely supply of one or more of the Company's CNS drug candidates to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture and commercialization of the Company's CNS drug candidates; and the risks more fully discussed in the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the

U.S. Securities and Exchange Commission (SEC). The Company's SEC filings are available on the SEC's website at [www.sec.gov](http://www.sec.gov). You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company's views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220712005491/en/): <https://www.businesswire.com/news/home/20220712005491/en/>

**Investors:**

Mark Flather  
Vice President, Investor Relations  
(650) 577-3617  
[mflather@vistagen.com](mailto:mflather@vistagen.com)

**Media:**

Nate Hitchings  
SKDK  
[nhitchings@skdknick.com](mailto:nhitchings@skdknick.com)

Source: VistaGen Therapeutics, Inc.